JAN 0 8 2003

file copy

PTO FORM 4/92 BORDAPTO - 1449 Page 1 of 1 **ATTY DOCKET: 10738-44** LIST OF PATENTS AND PUBLICATIONS SERIAL NO. APPLICANTS: Kersten M. Small et al FOR APPLICANT'S INFORMATION 09/636,259 FILING DATE: August 10, 2000 DISCLOSURE STATEMENT FOR: ALPHA-2A-ADRENERGIC **GROUP: 1634** RECEPTOR POLYMORPHISMS UNITED STATES LETTERS PATENT Exr. **DOCUMENT NUMBER** Init. DATE NAME SUB **CLASS** *(צע*נו 5 aa **CLASS** 5 8 0 Jan. 21, 1997 Weinshank et al JAN 1 0 2003 FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER **DATE** COUNTRY SUB ba WO 01 2 CLASS 0 8 2 April 26, 2001 **PCT** OTHER ART (INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.) HEINONEN P. et al: "Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects." The Journal of Clinical Endocrinology and Metabolism, United States, July BALDWIN C.T., et al: "Identification of a polymorphic glutamic acid stretch in the alpha2B-adrenergic receptor and lack of linkage with essential hypertension." American Journal of Hypertension: Journal of the American Society of Hypertension, United States, Sep. 1999, Vol. 12, No. 9, Pt. 1, pages 853-857. JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required CC for agonist-promoted phosphorylation and desensitization." Biochemistry, United States 19 Sep. 1995, Vol. 34, No. 37, 19 COMINGS, D.E., et al: "Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit cd hyperactivity disorder and learning disabilities in Tourette syndrome subjects." Clinical Genetics, Denmark, March 1999, Vol. MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension." Hypertension. United States, Jan. 1999, Vol. 33, No. 1, January 1999, pages 14-17. MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study." Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association-European Renal Association. England, Nov. 1999, Vol. 14, No. 11, pages 2657-2663. FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans." American Journal of Hypertension: Journal of the American Society of Hypertension. United States, Sep. 1995, Vol. 8, No. 9, pages 863-869. SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases ch G protein-coupled receptor kinase-mediated phosphorylation and desensitization." The Journal of Biological Chemistry. United States, 16 Feb 2001, Vol. 276, No. 7, pages 4917-4922. SNAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events." Journal of the American College of Cardiology. United States, May 2001, Vol. 37, No. 6, pages

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. 857464v1

10738-44

Diana B

3/5/03

1

PR 0 9 20	Use several sheets if nec		•	FILING August 10,		SROUP	1645	
AINER I	ARKO	(J.S. PATEN	DOCUMENTS				
AL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DAT	
3)	5,648,482	07/15/97	Meyer			RECE	IVE	D -
	5,846,710	12/08/98	Bajaj			ADD 1	0 2001	
	5,856,092	01/05/99	Dale et	al.	-	TOU OENT		
	5,888,819	03/30/99	Goelet	et al.		ECH CENH	1000/	2900
	5,981,174	11/09/99	Wolf et	al.	~			
	6,004,744	12/21/99	Goelet	et al.				
	6,013,431	01/11/00	Soderlu	ınd et al.	1			
M	6,156,503	12/05/00	Drazen	et al.				
		FOR	REIGN PATE	NT DOCUMENTS				
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSI YES	LATION NC
	ı							
		W.						
			-					
	OTHER DOCUM	ENTS (Includ	ing Author	, Title, Date, Pertine	nt Pages, Etc.)			
M	Limbird, L.E. (1988)	FASEB J 2, 2686	-2695.				,	
ש								
	Luttrell I M von Pie	Sen T Howes F	RF Dalla D	Pacca C I Internal D	K and Laftanit	, D I (1000) :	n Catachal	omi-
	Luttrell, L.M., van Bie Bridging Basic Science Press.	with Clinical M	edicine (Gol	dstein, D.S., Eisenhofe	r, G., and McCar	ty, R., eds) pp.	466-470, A	amme Acade
INER -	Jiana B			DATE CONSIDERED	3/5/03		· · · · · · · · · · · · · · · · · · ·	
.".								

(also form PTO-1449)

OIPE		Docket Number (Optional) 13092	Application Number 09/636,259			
	TION DISCLOSURE CITATION (Ese several sheets if necessary)	Applicant(s) Small et al.				
APR 0 9 2001		Filing Date August 10, 2000	Group Art Unit			
ENTHAL PADEMAR	OTHER DOCUMENTS (Including Author, 7	Title, Date, Pertinent Pages, Etc.)				
INTIPALE	Ruffolo, R.R., Jr., Nichols, A.J., Stadel, J.M., and	d Hieble, J.P. (1993) Annu Rev Phar				
Desp			RECEIVED			
	Hein, L., Altman, J.D., and Kobilka, B.K. (1999)	Nature 402, 181-184.	APR 1 0 2001			
			TECH CENTER 1600/2900			
	Altman, J.D., Trendelenburg, A.U., MacMillan, L., Bernstein, D., Limbird, L., Starke, K., Kobilka, B.K., and Hein, L. Mol. Pharmacol. 56, 154-161.					
	Lakhlani, P.P., MacMillan, L.B., Guo, T.Z., McC Acad Sci USA 94, 9950-9955.	Cool, B.A., Lovinger, D.M., Maze, M.	., and Limbird, L.E. (1997) Proc Natl			
	Holmes, B., Brogden, R.N., Heel, R.C., Speight, T.M., and Avery, G.S. (1983) Drugs 26, 212-229.					
	Dao, T.T., Kailasam, M.T., Parmer, R.J., Le, H.V., Le Verge, R., Kennedy, B.P., Ziegler, G., Insel, P.A., Wrigh O'Connor, D.T. (1998) J Hypertens 16, 779-792.					
	Goldstein, D.S., Grossman, E., Listwak, S., and Folio, C.J. (1991) Hypertension 18, III40-III48.					
	Lockette, W., Ghosh, S., Farrow, S., MacKenzie, S., Baker, S., Miles, P., Schork, A., and Cadaret, L. (1995) Am J Hype 8, 390-394.					
	Svetkey, L.P., Timmons, P.Z., Emovon, O., Anderson, N.B., Preis, L., and Chen, YT. (1996) Hypertension 27, 12					
	Liggett, S.B. (1998) Clin and Exp. Allergy 28, 77-	79.				
	Guyer, C.A., Horstman, D.A., Wilson, A.L., Clark, J.D., Cragoe, E.J.Jr., and Limbird, L.E. (1990) J Biol Chem 265, 17307-17317.					
DB) ""	Rutkowski, M.P., Klanke, C.A., Su, Y.R., Reif, M	., and Menon, A.G. (1998) Hyperten	nsion 31, 1230-1234.			
EXAMINER .	aBjohanse	DATE CONSIDERED 3	5 03			
	f citation considered, whether or not citation is in conform e copy of this form with next communication to applicant.		e through citation if not in conformance and			

			Docket Number (Optional) 13092	Application Number 09/636,259			
OILIE	FORM	MATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) Small et al.				
APR 0 9 20	soon E		Filing Date August 10, 2000	Group Art Unit			
*EXAMINER	Tu;		, Title, Date, Pertinent Pages, Etc.)	1010			
TRADEN	M	Eason, M.G. and Liggett, S.B. (1992) J.Biol.Che					
1200)			1	RECEIVED			
	1	Jewell-Motz, E.A. and Liggett, S.B. (1996) J.Bio	ol.Chem. 271, 18082-18087.	APR 1 0 2001			
			· · · · · · · · · · · · · · · · · · ·	TECH CENTER 1600/2900			
		de chasseval, R. and de Villartay, JP. (1991) Nu	ucleic Acids Research 20, 245-250.				
		Eason, M.G., Moreira, S.P., and Liggett, S.B. (19	Eason, M.G., Moreira, S.P., and Liggett, S.B. (1995) J.Biol.Chem. 270, 4681-4688.				
		Jewell-Motz, E.A., Donnelly, E.T., Eason, M.G., a	and Liggett, S.B. (1998) Biochem 37	, 15720-15725.			
	Schwinn, D.A., Page, S.O., Middleton, J.P., Cotecchia, S. (1991) Mol.Pharmacol. 40, 619		enz, W., Liggett, S.B., Yamamoto, K., 6.	Caron, M.G., Lefkowitz, R.J., and			
		Martin, T.F.J. (1983) J Biol Chem 258, 14816-14	4822.				
		Eason, M.G., Jacinto, M.T., Theiss, C.T., and Lig	ggett, S.B. (1994) Proc.Natl.Acad.Sci	i., USA 91, 11178-11182.			
		Smith, P.K., Krohn, R.I., Hermanson, G.T., Malli Olson, B.J., and Klenk, D.C. (1985) Anal. Biochen	ia, A.K., Gartner, F.H., Provenzano, m. 150, 76-85.	M.D., Fujimoto, E.K., Goeke, N.M.,			
		Eason, M.G. and Liggett, S.B. (1996) J.Biol.Chen	m. 271, 12826-12832.				
•		Exton, J.H. (1996) Annu Rev Pharmacol Toxicol	36, 481-509.				
1) DOD		MacMillan, L.B., Lakhlani, P., Lovinger, D., and I	Limbird, L.E. (1998) Recent Prog H	orm Res 53, 25-42.			
EXAMINER]	Dic	ina B	DATE CONSIDERED 3/5	-103			
*EXAMINER: I	nitial if (f citation considered, whether or not citation is in conform e copy of this form with next communication to applicant.	nance with MPEP Section 609; Draw line	through citation if not in conformance and			

SIPE		Docket Number (Optional) 13092	Application Number 09/636.259
1 /	WATION DISCLOSURE CITATION Use several sheets if necessary)	Applicant(s) Small et al.	
APR 0 9 200		Filing Date August 10, 2000	Group Art Unit 1645
NO THADENA	<u> </u>	Title, Date, Pertinent Pages, Etc.)	
(000)	Makaritsis, K.P., Johns, C., Gavras, I., Altman, J 405-407.	J.D., Handy, D.E., Bresnahan, M.R.,	and Gavras, H. (1999) Hypertension 34, RECEIVED
	Spiegel, A.M. (1996) Annu Rev Physiol 58, 143-1	170.	APR 1 0 2001
			TECH CENTER 1600/2900
	Kotanko, P., Binder, A., Tasker, J., DeFreitas, P. 30, 773-776.	, Kamdar, S., Clark, A.J., Skrabal, F	., and Caulfield, M. (1997) Hypertension
	Liggett, S.B., Wagoner, L.E., Craft, L.L., Hornur 102, 1534-1539.	ng, R.W., Hoit, B.D., McIntosh, T.C.	, and Walsh, R.A. (1998) J Clin Invest
	Tan, S., Hall, I.P., Dewar, J., Dow, E., and Lipwo	orth, B. (1997) Lancet 350, 995-999.	
	Green, S.A., Cole, G., Jacinto, M., Innis, M., and	Liggett, S.B. (1993) J Biol Chem 26	8, 23116-23121.
	Shenker, A., Laue, L., Kosugi, S., Merendino, J.J. "Introduction to 2- adrence pto	(93)"	and and
	http://www.adrenoceptor.com/alphaintro.htm (Robinson, E. and Hudson, A. "Adhttp://www.tocris.com/adrenoceptor.htm, (vis	visited April 2, 2001) Irenoceptor Pharmace	(PP. N/A) (author N/A)
M	http://www.tocris.com/adrenoceptor.htm (vis	ited March 12, 2001) (mber 1998)	PP. NIA)
EXAMINER) ina B	DATE CONSIDERED 3(50	3
	l if citation considered, whether or not citation is in conform ude copy of this form with next communication to applicant.		through citation if not in conformance and